BR112022024404A2 - Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus - Google Patents

Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Info

Publication number
BR112022024404A2
BR112022024404A2 BR112022024404A BR112022024404A BR112022024404A2 BR 112022024404 A2 BR112022024404 A2 BR 112022024404A2 BR 112022024404 A BR112022024404 A BR 112022024404A BR 112022024404 A BR112022024404 A BR 112022024404A BR 112022024404 A2 BR112022024404 A2 BR 112022024404A2
Authority
BR
Brazil
Prior art keywords
particle
cancer
treatment
arenavirus
picv
Prior art date
Application number
BR112022024404A
Other languages
English (en)
Inventor
Matushansky Igor
Hwang Andy
Katchar Kianoosh
Edwards Donna
LAUTERBACH Henning
Schwendinger Michael
Orlinger Klaus
Schmidt Sarah
Berka Ursula
Iacobucci Corinne
Schlienger Katia
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of BR112022024404A2 publication Critical patent/BR112022024404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MÉTODO PARA TRATAR CÂNCER, SEQUÊNCIA DE NUCLEOTÍDEOS, CÉLULA HOSPEDEIRA, PARTÍCULA DE LCMV, PARTÍCULA DE PICV, COMPOSIÇÃO FARMACÊUTICA, PARTÍCULA DE ARENAVÍRUS. O presente pedido se refere, de modo geral, a estratégias para tratamento de câncer com o uso de partículas de arenavírus. As estratégias de tratamento descritas no presente documento são para tratar câncer, incluindo carcinoma de células escamosas de cabeça e pescoço, com o uso de partículas de arenavírus trissegmentadas que codificam um antígeno de papilomavírus humano (HPV). As estratégias de tratamento descritas no presente documento podem incluir administração de um inibidor de ponto de verificação imunológico.
BR112022024404A 2020-05-29 2021-05-12 Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus BR112022024404A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032362P 2020-05-29 2020-05-29
US202163173155P 2021-04-09 2021-04-09
US202163175842P 2021-04-16 2021-04-16
PCT/EP2021/062728 WO2021239471A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Publications (1)

Publication Number Publication Date
BR112022024404A2 true BR112022024404A2 (pt) 2023-02-07

Family

ID=75914543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024404A BR112022024404A2 (pt) 2020-05-29 2021-05-12 Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Country Status (12)

Country Link
US (1) US20230346906A1 (pt)
EP (1) EP4157342A1 (pt)
JP (1) JP2023527083A (pt)
KR (1) KR20230046278A (pt)
AU (1) AU2021282287A1 (pt)
BR (1) BR112022024404A2 (pt)
CA (1) CA3184791A1 (pt)
CR (1) CR20220602A (pt)
IL (1) IL298420A (pt)
MX (1) MX2022014725A (pt)
PE (1) PE20240647A1 (pt)
WO (1) WO2021239471A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592205B2 (en) 2007-12-27 2013-11-26 Universitat Zurich Replication-defective arenavirus vectors
HUE054579T2 (hu) 2013-12-03 2021-09-28 Hookipa Biotech Gmbh CMV vakcinák
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
WO2023152116A1 (en) * 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778903A1 (en) 2014-11-13 2021-02-17 Université de Genève Tri-segmented arenaviruses as vaccine vectors
WO2016198531A2 (en) * 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
EP3458593A1 (en) 2016-05-18 2019-03-27 Hookipa Biotech GmbH Tri-segmented pichinde viruses as vaccine vectors
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
CR20220602A (es) 2023-05-16
MX2022014725A (es) 2023-02-09
WO2021239471A9 (en) 2022-01-13
KR20230046278A (ko) 2023-04-05
EP4157342A1 (en) 2023-04-05
WO2021239471A1 (en) 2021-12-02
AU2021282287A1 (en) 2023-01-05
IL298420A (en) 2023-01-01
JP2023527083A (ja) 2023-06-26
CA3184791A1 (en) 2021-12-02
PE20240647A1 (es) 2024-04-04
US20230346906A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112022024404A2 (pt) Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
MX2021015675A (es) Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
MX2021001883A (es) Virus recombinantes del mixoma y usos de los mismos.
EP4141111A4 (en) VACCINE AGAINST ONCOLYTIC VIRUS AND DRUGS FOR THE TREATMENT OF TUMORS BY COMBINING THE VACCINE AGAINST ONCOLYTIC VIRUS WITH IMMUNE CELLS
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
WO2007064900A3 (en) Treatment of lesions or imperfections in mammalian skin or near-skin tissues or in or near other anatomic surfaces
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
BR112021008179A2 (pt) Construtos plasmídicos para tratamento contra câncer e métodos de uso
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
MX2020013901A (es) Virus oncolítico o antígeno que presenta terapia contra el cáncer mediada por células usando interferón tipo i y lingado de cd40.
PH12019502522A1 (en) Oncolytic virus and method
MX2021008396A (es) Composiciones de administración farmacéutica y sus usos.
MX2015013784A (es) C. novyi para el tratamiento de tumores solidos en humanos.
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
NZ757442A (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
MY196026A (en) Stem Cell Conditioned Media for Clinical and Cosmetic Applications
WO2014081346A3 (en) Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus